Advertisement

Pneumo News

, Volume 10, Issue 2, pp 27–31 | Cite as

Interaktionen zwischen Lunge und Herz

COPD und kardiovaskuläre Komorbiditäten

  • Peter Alter
  • Claus F. Vogelmeier
  • Rudolf A. Jörres
fortbildung
First Online:
  • 65 Downloads

Die COPD tritt häufig mit Komorbiditäten auf, insbesondere mit solchen kardiovaskulärer Art. Neben den bekannten Einflüssen auf den rechten Ventrikel rücken zunehmend prima vista subklinische Veränderungen des linken Ventrikels in den Blick. Die zugrundeliegenden Mechanismen werden derzeit erforscht. In der multizentrischen COSYCONET-Kohorte zeigten sich direkte Einflüsse von Obstruktion und Überblähung auf den linken Ventrikel und die elektrischen Herzachsen im EKG.

This is a preview of subscription content, log in to check access.

Literatur

  1. 1.
    Vanfleteren LE, Spruit MA, Groenen M et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187(7):728–35CrossRefGoogle Scholar
  2. 2.
    Divo M, Cote C, de Torres JP et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(2):155–61CrossRefGoogle Scholar
  3. 3.
    Feary JR, Rodrigues LC, Smith CJ et al. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax. 2010;65(11):956–62CrossRefGoogle Scholar
  4. 4.
    Bursi F, Vassallo R, Weston SA et al. Chronic obstructive pulmonary disease after myocardial infarction in the community. Am Heart J. 2010;160(1):95–101CrossRefGoogle Scholar
  5. 5.
    Fisher KA, Stefan MS, Darling C et al. Impact of COPD on the mortality and treatment of patients hospitalized with acute decompensated heart failure: the Worcester Heart Failure Study. Chest. 2015;147(3):637–45CrossRefGoogle Scholar
  6. 6.
    Iversen KK, Kjaergaard J, Akkan D et al. The prognostic importance of lung function in patients admitted with heart failure. Eur J Heart Fail. 2010;12(7):685–91CrossRefGoogle Scholar
  7. 7.
    Hawkins NM, Huang Z, Pieper KS et al. Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Eur J Heart Fail. 2009;11(3):292–8CrossRefGoogle Scholar
  8. 8.
    Lim KP, Loughrey S, Musk M et al. Beta-blocker under-use in COPD patients. Int J Chron Obstruct Pulmon Dis. 2017;12:3041–6CrossRefGoogle Scholar
  9. 9.
    Terzano C, Conti V, Di Stefano F et al. Comorbidity, hospitalization, and mortality in COPD: results from a longitudinal study. Lung. 2010;188(4):321–9CrossRefGoogle Scholar
  10. 10.
    Adesanoye DT, Willey CJ. Does Cardiovascular Comorbidity Influence the Prescribing of Bronchodilators in Chronic Obstructive Pulmonary Disease? Ann Pharmacother. 2017;51(10):855–61CrossRefGoogle Scholar
  11. 11.
    Wise RA, Anzueto A, Cotton D et al. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med. 2013;369(16):1491–501CrossRefGoogle Scholar
  12. 12.
    Papi A, Jones PW, Dalvi PS et al. The EFFECT trial: evaluating exacerbations, biomarkers, and safety outcomes with two dose levels of fluticasone propionate/formoterol in COPD. Int J Chron Obstruct Pulmon Dis. 2015;10:2431–8CrossRefGoogle Scholar
  13. 13.
    Calverley PM, Anderson JA, Celli B et al. Cardiovascular events in patients with COPD: TORCH study results. Thorax. 2010;65(8):719–25CrossRefGoogle Scholar
  14. 14.
    Brook RD, Anderson JA, Calverley PM et al. Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk. Heart. 2017;103(19):1536–42CrossRefGoogle Scholar
  15. 15.
    Vogelmeier CF, Gaga M, Aalamian-Mattheis M et al. Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial. Respir Res. 2017;18(1):140CrossRefGoogle Scholar
  16. 16.
    de Lucas-Ramos P, Izquierdo-Alonso JL, Rodriguez-Gonzalez Moro JM et al. Chronic obstructive pulmonary disease as a cardiovascular risk factor. Results of a case-control study (CONSISTE study). Int J Chron Obstruct Pulmon Dis. 2012;7:679–86PubMedPubMedCentralGoogle Scholar
  17. 17.
    Mullerova H, Agusti A, Erqou S, Mapel DW. Cardiovascular comorbidity in COPD: systematic literature review. Chest. 2013;144(4):1163–78CrossRefGoogle Scholar
  18. 18.
    Miller J, Edwards LD, Agusti A et al. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med. 2013;107(9):1376–84CrossRefGoogle Scholar
  19. 19.
    Vaes AW, Spruit MA, Theunis J et al. Endothelial function in patients with chronic obstructive pulmonary disease: a systematic review of studies using flow mediated dilatation. Expert Rev Respir Med. 2017;11(12):1021–31PubMedGoogle Scholar
  20. 20.
    Fisk M, McEniery CM, Gale N et al. Surrogate Markers of Cardiovascular Risk and Chronic Obstructive Pulmonary Disease: A Large Case-Controlled Study. Hypertension. 2018;71(3):499–506CrossRefGoogle Scholar
  21. 21.
    Miniati M, Monti S, Pavlickova I, Bottai M. Survival in COPD: impact of lung dysfunction and comorbidities. Medicine (Baltimore). 2014;93(12):e76CrossRefGoogle Scholar
  22. 22.
    Lange P, Nyboe J, Jensen G et al. Ventilatory function impairment and risk of cardiovascular death and of fatal or non-fatal myocardial infarction. Eur Respir J. 1991;4(9):1080–7PubMedGoogle Scholar
  23. 23.
    Weitzenblum E, Chaouat A. Cor pulmonale. Chron Respir Dis. 2009;6(3):177–85CrossRefGoogle Scholar
  24. 24.
    Weitzenblum E, Chaouat A, Canuet M, Kessler R. Pulmonary hypertension in chronic obstructive pulmonary disease and interstitial lung diseases. Semin Respir Crit Care Med. 2009;30(4):458–70CrossRefGoogle Scholar
  25. 25.
    Watz H, Waschki B, Meyer T et al. Decreasing cardiac chamber sizes and associated heart dysfunction in COPD: role of hyperinflation. Chest. 2010;138(1):32–8CrossRefGoogle Scholar
  26. 26.
    Kawut SM, Poor HD, Parikh MA et al. Cor pulmonale parvus in chronic obstructive pulmonary disease and emphysema: the MESA COPD study. J Am Coll Cardiol. 2014;64(19):2000–9CrossRefGoogle Scholar
  27. 27.
    Karch A, Vogelmeier C, Welte T et al. The German COPD cohort COSYCONET: Aims, methods and descriptive analysis of the study population at baseline. Respir Med. 2016;114:27–37CrossRefGoogle Scholar
  28. 28.
    Kahnert K, Lucke T, Huber RM et al. Relationship of hyperlipidemia to comorbidities and lung function in COPD: Results of the COSYCONET cohort. PLoS One. 2017;12(5):e0177501CrossRefGoogle Scholar
  29. 29.
    Kahnert K, Lucke T, Biertz F et al. Transfer factor for carbon monoxide in patients with COPD and diabetes: results from the German COSYCONET cohort. Respir Res. 2017;18(1):14CrossRefGoogle Scholar
  30. 30.
    Alter P, Jörres RA, Watz H et al. Left ventricular volume and wall stress are linked to lung function impairment in COPD. Int J Cardiol. 2018; in printGoogle Scholar
  31. 31.
    Alter P, Watz H, Kahnert K et al. Airway obstruction and lung hyperinflation in COPD are linked to an impaired left ventricular diastolic filling. Respir Med. 2018 Feb 19; https://doi.org/10.1016/j.rmed.2018.02.011Google Scholar
  32. 32.
    Stone IS, Barnes NC, James WY et al. Lung Deflation and Cardiovascular Structure and Function in Chronic Obstructive Pulmonary Disease. A Randomized Controlled Trial. Am J Respir Crit Care Med. 2016;193(7):717–26CrossRefGoogle Scholar
  33. 33.
    Hohlfeld JM, Vogel-Claussen J, Biller H et al. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial. Lancet Respir Med. 2018 Feb 21; https://doi.org/10.1016/S2213-2600(18)30054-7Google Scholar
  34. 34.
    Rabe KF, Watz H. Chronic obstructive pulmonary disease. Lancet. 2017;389(10082):1931–40CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  • Peter Alter
    • 1
  • Claus F. Vogelmeier
    • 1
  • Rudolf A. Jörres
    • 2
  1. 1.Klinik für Innere Medizin, Pneumologie und IntensivmedizinPhilipps-Universität MarburgMarburgDeutschland
  2. 2.Institut und Poliklinik für Arbeits-, Sozial- und Umweltmedizin, Klinikum InnenstadtLudwig-Maximilians-Universität München, Comprehensive Pneumology Center (CPC) MünchenMünchenDeutschland

Personalised recommendations

Cite article

Buy options